In addition to functioning as the guardian of the genome, TP-53 may have tumor-suppressing properties stemming from the regulation of immune responses, and p53 mutations may reduce immunosurveillance and create a cancer-promoting immunosuppressing microenvironment [121] (in parallel with MDS [87]). The gene discussed is TP53; the disease is myelodysplastic syndrome.